期刊文献+

基质金属蛋白酶-9和内皮素-1评价冠状动脉内支架术后再狭窄的意义 被引量:6

The significance of matrix metalloproteinase-9 and endothelin-1 in evaluating the in-stent restenosis after percutaneous coronary intervention procedure
下载PDF
导出
摘要 目的探讨动态检测基质金属蛋白酶(MMP)-9、内皮素(ET)-1在经皮冠脉介人术(PCI)后再狭窄的意义。方法对30例经皮冠脉介人术后患者进行造影及光学相干断层成像(OCT)检查随访,造影证实再狭窄5例,共7处病变;无再狭窄25例,共34处病变。测量并比较两组内膜组织覆盖厚度、最狭窄处血管管腔面积、最狭窄处支架面积等,计算支架的最大内膜组织覆盖面积及支架的内膜组织覆盖面积百分比。术前及随访时均行MMP-9及ET-1检测,比较两组PCI前后MMP-9和ET-1的变化。结果与无再狭窄组比较,再狭窄组有更大的内膜组织覆盖厚度、内膜组织覆盖面积及更少的最小管腔面积。术前再狭窄组和非再狭窄组的MMP一9和ET—l浓度均无明显差异;术后再狭窄组的MMP一9、ET一1浓度明显高于非再狭窄组(P〈O.05);术后再狭窄组MMP-9、ET-1浓度较术前明显升高(P〈0.05);非再狭窄组术后MMP-9、ET-1浓度较术前均无明显变化。多因素Logistic回归分析显示,冠状动脉支架术后支架内再狭窄可能与MMP-9水平(P〈0.01,OR=1.84,95%CI:1.38-2.43)和ET-1水平(P〈0.0l,OR=1.37,95%CI:1.19~2.57)呈正相关。结论PCI后支架内再狭窄患者MMP-9和ET-1水平较术前升高。MMP-9及ET-1可作为预测冠脉再狭窄的参考指标。 Objective To discuss the relationship between the concentration of matrix metalloproteinase, endotheli-1 and the in-stent restenosis after percutaneous coronary .intervention procedure (PCI). Methods PCI procedure was carried out in 30 patients with coronary artery disease in hospital. After the procedure, both coronary angiography and optical coherence tomography (OCT) were conducted during follow-up period. Base on the coronary angiography findings, in-stent restenosis (ISR) was confirmed in 5 cases with a total of 7 lesions (ISR group), while no in-stent restenosis (non-ISR) was seen in 25 cases with a total of 34 lesions (non-ISR group). The measurement indexes contain the maximal neointimal hyperplasia thickness of stent, minimal lumen cross-sectional area, steut cross-sectional area. And then the neointimal byperplasia area, the percentage of the area of the neointimal, diameter stenosis ratio were calculated before and after the treatment, and MMP-1 and ET-1 levels were determined. The changes in MMP-1 and ET-1 levels after PCI in each group were compared. Results Both the maximal neointimal hyperplasia thickness of stent and neointimal hyperplasia area were significantly larger, while the LA was significantly smaller, in ISR group than those in non-ISR group(P〈0.05). Before PCI no significant differences in the concentration of MMP-1 and ET-1 were detected between the ISR and non-ISR groups. The concentration of MMP-9 and ET-1 in ISR group were obviously higher than that in non-ISR group (P〈0.05). In ISR group, the concentration of MMP-9 and ET-1 before PCI were obviously increased than that after PCI (P〈 0.05 ), while no obvious changes in MMP-9 and ET-1 level were found in non-ISR group. Multiple logistic stepwise regression analysis showed that there was a positive correlation among the levels of MMP-9 (P〈0.01, OR= 1.84, 95%CI:1.38-2.43) and ET-1 (P〈O.01, OR=1.37, 95%CI: 1.19-2.57) and ISR. Conclusion After PCI the increases of MMP-9 and ET-1 concentration bear a close relationship to the degree of restenosis.
出处 《中国心血管病研究》 CAS 2013年第7期484-488,共5页 Chinese Journal of Cardiovascular Research
基金 沈阳市科技计划项目(项目编号:F11-262-9-50)
关键词 基质金属蛋白酶 内皮素 经皮冠状动脉介入治疗 再狭窄 光学相干断层成像 Matrix metalloproteinase-9 Endotheli-1 Percutaneous coronary intervention In-stentrestenosis Optical coherence tomography
  • 相关文献

参考文献17

  • 1Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol, 2006,59 : 232-239.
  • 2Tearney GJ, Jang IK, Bouma BE. Optical coherence tomography for imaging: the vulnerable plaque. J Biomed Opt,2006,11: 021002.
  • 3Teirstein PS, Massullo V, Jani S, et al. Catheter-based radio- therapy to inhibit restenosis after coronary stenting. N Engl J Med, 1997,336 : 1697-1703.
  • 4Koster R, Vieluf D, Kiehn M, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet, 2000,356 : 1895-1897.
  • 5Drachman DE, Simon DI. Inflammation as a mechanism and ther- apeutic target for in-stent restenosis. Curr Atheroscler Rep, 2005,7 : 44-49.
  • 6侯旭敏,刘华,关韶峰,仇兴标,陈晖,方唯一.基质金属蛋白酶-1与冠状动脉斑块稳定性的相关研究[J].中国心血管病研究,2007,5(12):889-891. 被引量:3
  • 7Feldman LJ, Deux JF, Jacob MP, et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation,2001, 103 : 3117-3122.
  • 8Bonello L, De Labriolle A, Lemeslc G, et al. Intravascular ul- trasound-guided percutaneous coronary interventions in contem- porary practice. Arch Cardiovase Dis, 2009,102 : 143-151.
  • 9Jones GT, Kay IP, Chu JW. Elevated plasma active matrix - metalloproteinase -9 level is associated with coronary artery in- stent restenosis. Arterioseler Thromb Vasc Biol,2006,26:e121- 125.
  • 10Jones GT, Tarr GP, Phillips LV, et al. Active matrix metallo- proteinases 3 and 9 are independently associated with coronary artery in-stent restenosis. Atherosclerosis, 2009,207 : 603-607.

二级参考文献29

  • 1葛均波,刘学波.药物洗脱支架的临床应用[J].中国循环杂志,2005,20(2):156-157. 被引量:2
  • 2马会利,葛均波,钱菊英,孙爱军,牛玉宏,马永莉,方业明,冯军,黄宝晨,王克强.冠心病患者首次经皮冠状动脉介入治疗后支架内再狭窄的随访研究[J].中国介入心脏病学杂志,2005,13(5):332-332. 被引量:6
  • 3[1]Pasterkamp G,Falk E,Woutman H,et al.Techniques characterizing the coronary atherosclerotic plaque:influence on clinical decision making? J Am Coll Cardiol,2000,36:13-21.
  • 4[2]Conti CR.Updated pathophysiologic concepts in unstable coronary artery disease.Am Heart J,2001,141:12-14.
  • 5[3]Dolley CM,McEwan JR,Henney AM.Matrix metalloprotease and cardiovascular disease.Circ Res,1995,77:863-868.
  • 6[4]Sbu Ye.Polymorphism in matrix metalloproteinase gene promoters:implication in regulation of gene expression and susceptibility of various diseases.Matrix Biol,2000,19:623-629.
  • 7[5]Sukhova GK,Schonbeck U,Rabkin E,et al.Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.Circulation,1999,99:2503-2509.
  • 8[7]Inoue T,Kato T,Takayanagi K,et al.Circulating matrix metalloproteinase-1 and loproteinase-3 in patients with an acute coronary syndrome.Am J Cardiol,2003,92:461-464.
  • 9[1]Zhou YF,Leon MB,Waclawiw MA,et al.Association betweenprior cytomegalovirus infection and the risk of restenosis after coronary atherectomy.N Sngl J Med,1996,335:624-630.
  • 10[2]Manegold C,Alwazzeh M,Jablonowski H,et al.Prior cytomegalovirus infection and the risk of restenosis after percutaneous transluminal.coronary balloon angioplasty.Circulation,1999,99:1290-1294.

共引文献11

同被引文献47

  • 1Bulum J,Ernst A,Strozzi M.The impact of successful manual thrombus aspiration on in-stent restenosis after primary PCI:angiographic and clinical follow-up[J].Coron Artery Dis,2012,23(7):487-491.
  • 2Chatterjee S.Regarding Immunosuppressive Therapy to Prevent Restenosis after PCI[J].Am J Med,2012,125(1):e17.
  • 3Li S,Zhang S,Li N,et al.Arterial smooth muscle injury causes blood tissue factor elevation predicting restenosis after pci[J].Scand Cardiovasc J,2012,46(2):87-92.
  • 4Kwon JS,Kim YS,Cho AS,et al.Origin of restenosis after drugeluting stent implantation in hyperglycemia is inflammatory cells and thrombus[J].J Atheroscler Thromb,2010,18(7):604-615.
  • 5Perkins LE.Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems[J].Vet Pathol,2010,47(1):58-76.
  • 6Guerra E,Byrne RA,Kastrati A.Pharmacological inhibition of coronary restenosis:systemic and local approaches[J].Expert Opin Pharmacother,2014,15(15):2155-2171.
  • 7Lupi A,Secco GG,Rognoni A,et al.Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention[J].J Thromb Thrombolysis,2012,33(4):308-317.
  • 8Jukema JW,Verschuren JJ,Ahmed TA,et al.Restenosis after PCI.Part 1:pathophysiology and risk factors[J].Nat Rev Cardiol,2011,9(1):53-62.
  • 9Gutman D,Golomb G.Liposomal alendronate for the treatment of restenosis[J].J Control Release,2012,161(2):619-627.
  • 10Katsaros KM,Kastl SP,Zorn G,et al.Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and-9[J].JACC Cardiovasc Interv,2010,3(1):90-97.

引证文献6

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部